Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.

@article{Berg2006ExtendedTD,
  title={Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.},
  author={Thomas Berg and Michael von Wagner and Samer S Nasser and Christoph Sarrazin and Tobias Heintges and Tilman J{\"o}rn Gerlach and Peter Buggisch and Tobias Goeser and Jens W F Rasenack and Gerd Rudolf Pape and Wolfgang Schmidt and Birgit Kallinowski and Hartwig H F Klinker and Ulrich Spengler and Peter Martus and Ulrich Alshuth and Stefan Zeuzem},
  journal={Gastroenterology},
  year={2006},
  volume={130 4},
  pages={1086-97}
}
BACKGROUND & AIMS The treatment of patients infected with hepatitis C virus (HCV) type 1 remains a challenge necessitating innovative strategies to improve treatment outcome. The extension of treatment duration beyond 48 weeks is one possible strategy to address this problem. METHODS The efficacy and safety of 48 weeks (group A, N = 230) vs 72 weeks (group B, N = 225) of treatment with pegylated-interferon-alfa-2a (180 microg/wk) plus ribavirin (800 mg/day) were studied in treatment-naive… CONTINUE READING